Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo

BACKGROUND: Glioblastoma is the most frequent and most malignant brain tumor with the patients having a median survival of only 14.6 months. Although glioblastoma patients are treated with surgery, radiation and chemotherapy recurrence is inevitable. A stem-like population of radio- and chemoresista...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Stine S., Petterson, Stine A., Halle, Bo, Aaberg-Jessen, Charlotte, Kristensen, Bjarne W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341392/
https://www.ncbi.nlm.nih.gov/pubmed/28270132
http://dx.doi.org/10.1186/s12885-017-3162-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341392/
https://www.ncbi.nlm.nih.gov/pubmed/28270132
http://dx.doi.org/10.1186/s12885-017-3162-3

Ejemplares similares